Evaluating successful achievement of therapeutic mycophenolate trough levels in kidney transplant patients receiving cyclosporine and tacrolimus during six month after transplantation

Abstract

Introduction: Kidney transplantation is the choiced treatment for chronic renal failure. Mycophenolate is an important drug in kidney transplantation and has a narrow therapeutic range. However, the role of monitoring of mycophenolate in the patient’s drug diet has not been established to increase drug efficacy and reduce its toxicity. Usually not measured. But if measured,it should be measured accurately. Aim: Evaluating successful achievement of therapeutic mycophenolate trough levels in kidney transplant patients receiving cyclosporine or tacrolimus Materials and method: This study was based on 100 patients who received the kidney transplant in the first month and in their transplant regimen they received mycophenolate with cyclosporine or tacrolimus. After considering inclusion and exclusion criteria the demographic and clinical and labartory data of the selected patients were recorded. Blood samples were taken from each patient twice, on the thired day and on discharge. Separated and freeze blood serum patients. Serum concentrations of MPA was measured with fluorescence method. Result: In this study patients divided into two groups, 56 patients received cyclosporine and 44 patients received tacrolimus. There were no significant demographic and clinical differences between groups. Mean serum level of mycophenolat in 3rd day of transplantation in general patient is 2.54±2.36 and in 14th day of transplantation in general patient is 3.47±3.54 which was in therapeutic range. Conclusion: Despite level monitoring mycophenolate trough in cyclosporine or tacrolimus group. mycophenolate level was in acceptable therapeutic range (1-3.5 mg/l) in this therapeutic range were not seen hematologic and gastrointestinal adverse effect.